Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II first-line arsenic trioxide for chronic graft-versus-host disease
2016-002358-18Phase 2Completed
- Sponsor
- Medsenic
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in chronic graft-versus-host disease (cGVHD), sponsored by Medsenic. Primary endpoint: Response rate at 6 months. Started Nov 2016; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2016-002358-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002358-18.